Article
Ponatinib reduces viability, migration, and functionality of human endothelial cells.
Leukemia & lymphoma - 1 Jun 2017
Gover-Proaktor Ayala, Granot Galit, Shapira Saar, Raz Oshrat, Pasvolsky Oren, Nagler Arnon, Lev Dorit L, Inbal Aida, Lubin Ido, Raanani Pia, Leader Avi
Abstract excerpt
Tyrosine kinase inhibitors (TKIs) have revolutionized the prognosis of chronic myeloid leukemia. With the advent of highly efficacious therapy, the focus has shifted toward managing TKI adverse effects, such as vascular adverse events (VAEs). We used an in vitro angiogenesis model to investigate the TKI-associated VAEs. Our data show that imatinib, nilotinib, and ponatinib reduce human umbilical vein endothelial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.